Why Is SAREPTA THERAPEUTICS (SRPT) Stock Down Today?
By the Top Tier Newswire AI Desk · September 8, 2026 at 10:20 AM ET · reviewed against 3 wire stories
SAREPTA THERAPEUTICS (SRPT) is down -9.89% in the latest session. Our newswire has captured 3 stories on SRPT across 3 sources in the last 36 hours, with AI sentiment reading bearish (avg 39/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Sarepta Therapeutics (SRPT) stock fell 9.89% to $20.27 in early trading on September 9, 2026, driven by a broader biotech selloff following a major trial failure at Novartis. The market reacted sharply to news that Novartis' del-desiran phase 3 trial failed to meet primary endpoints, dragging down shares of related biotech firms including Sarepta. The stock opened with a -9.8% gap down from the prior close of $22.50, reaching an intraday low of $19.30 before stabilizing slightly.
What Happened
Sarepta’s decline came amid a broader sector-wide pullback. The failure of Novartis' del-desiran trial triggered a sell-off in biotech stocks, with Novartis itself falling 13%. Sarepta, which has a market cap of $2.4 billion and a history of unprofitability (TTM EPS -1.32), was caught in the crossfire. The stock’s intraday performance reflected immediate investor concern, with volume at 0.9 million shares, three times the 3-month average. The session high of $21.30 at 7:20 AM ET gave way to a steady decline, ending the session near $20.21.
What The Data Shows
Sarepta’s fundamentals remain weak, with TTM revenue declining 20.4% and a net margin of -6.9%. The stock is currently trading within its 52-week range of $14.68 to $25.32. On July 28, the company appointed Michael Severino as CEO, succeeding Doug Ingram, but that event has not yet translated to improved performance. Meanwhile, the stock printed seven fresh 52-week highs on September 8, highlighting recent volatility. Congressional trades in the last 90 days included one buy and two sells by Donald J. Trump, the most recent on August 22.
What To Watch
Sarepta’s next key event will be its upcoming earnings release, which is not yet scheduled. Investors should monitor coverage breadth for any shift in sentiment or new catalysts.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →